Updated on 19 January 2016
Telephus Medical LLC, a California-based biotechnology company focused on development of antibody therapies for antibiotic-resistant staphylococcal infections, has announced that the Japan Patent Office has issued Japanese patent number 5,837,215 covering monoclonal antibody compositions that bind and neutralize the endo-β-N-acetylglucosaminidase (Gmd) subunit of staphylococcal bifunctional autolysin and methods to use those antibodies for the treatment and prevention of severe, life-threatening staph infections, including those caused by methicillin-resistantStaphylococcus aureus (MRSA).
These monoclonal antibody candidates represent the first of a series of antibodies designed by Telephus to fight severe staphylococcal biofilm infections resistant to modern antibiotics.
The Gmd target enzyme neutralized by these antibodies plays roles in surface and tissue attachment of bacteria, bacterial cell replication, immune evasion, virulence and biofilm formation, all of which drive the underlying pathology among patients suffering from severe infections caused by staphylococcal bacteria.
Neutralizing antibodies, such as those being developed by Telephus, both bind to a target enzyme, and inhibit that target enzyme's activity. These antibodies are potentially important for treating infections in patients who are immunocompromised due to age, trauma, existing medications, or other conditions such as diabetes, in which host production of antibodies against staphylococcal infections is likely to be impaired.
In animal models of severe implant-associated osteomyelitis biofilm infections similar to those found in some patients with hip or knee replacements, this neutralizing activity has been shown to accelerate bacterial clearance by the host immune system, suppress bone loss, reduce abscess formation and inhibit bacterial growth in bone and adjoining muscle tissue proximal to the site of implant infection.